These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1966729)

  • 41. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage.
    Kirchengast M; Rübsamen K; Lehmann HD
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):687-94. PubMed ID: 7506319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for functional 5-HT2 receptor sites on human blood platelets.
    De Clerck F; Xhonneux B; Leysen J; Janssen PA
    Biochem Pharmacol; 1984 Sep; 33(17):2807-11. PubMed ID: 6466388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis.
    Herve P; Humbert M; Sitbon O; Parent F; Nunes H; Legal C; Garcia G; Simonneau G
    Clin Chest Med; 2001 Sep; 22(3):451-8. PubMed ID: 11590840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.
    Pawlak D; Pawlak K; Chabielska E; Małyszko J; Takada A; Myśliwiec M; Buczko W
    Thromb Res; 1998 Jun; 90(6):259-70. PubMed ID: 9700856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Serotonin receptors blocker ketanserin in the combined therapy of patients with chronic obstructive bronchitis].
    Efimov VV; Blazhko VI; Voeĭkdova LS; Liashenko MM; Bondar' TN
    Klin Med (Mosk); 1991 May; 69(5):63-5. PubMed ID: 1649935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.
    De Clerck F; van Nueten JM; Reneman RS
    Agents Actions; 1984 Dec; 15(5-6):612-26. PubMed ID: 6397984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serotonin 5-HT2 receptors and brain circulation.
    Wiernsperger N
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S20-4. PubMed ID: 1369712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-Hydroxytryptamine dominates over thromboxane A2 in reducing collateral blood flow by activated platelets.
    Loots W; De Clerck F
    Am J Physiol; 1993 Jul; 265(1 Pt 2):H158-64. PubMed ID: 8342629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombosis and the role of the platelet.
    Becker RC
    Am J Cardiol; 1999 May; 83(9A):3E-6E. PubMed ID: 10357574
    [No Abstract]   [Full Text] [Related]  

  • 50. Platelet Function in Thrombosis and Hemostasis.
    Hvas AM
    Semin Thromb Hemost; 2016 Apr; 42(3):183-4. PubMed ID: 27023375
    [No Abstract]   [Full Text] [Related]  

  • 51. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
    Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
    Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet amplification of vasospasm.
    Weyrich AS; Solis GA; Li KS; Tulenko TN; Santamore WP
    Am J Physiol; 1992 Aug; 263(2 Pt 2):H349-58. PubMed ID: 1510131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
    Lüscher TF; Tanner FC; Bühler FR
    Dtsch Med Wochenschr; 1992 Apr; 117(18):710-9. PubMed ID: 1572260
    [No Abstract]   [Full Text] [Related]  

  • 54. Platelet and lymphocyte free intracellular calcium in affective disorders.
    Eckert A; Gann H; Riemann D; Aldenhoff J; Müller WE
    Eur Arch Psychiatry Clin Neurosci; 1994; 243(5):235-9. PubMed ID: 8172937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Amplification and desensitization in platelet activation].
    Wu QX
    Sheng Li Ke Xue Jin Zhan; 1992 Jul; 23(3):199-203. PubMed ID: 1299958
    [No Abstract]   [Full Text] [Related]  

  • 56. The possible role of serotonin 5HT2 receptor antagonism in cardioprotection.
    Noble MI; Drake-Holland AJ
    Neth J Med; 1992 Oct; 41(3-4):183-9. PubMed ID: 1470290
    [No Abstract]   [Full Text] [Related]  

  • 57. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury.
    Willerson JT; Yao SK; McNatt J; Benedict CR; Anderson HV; Golino P; Murphree SS; Buja LM
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10624-8. PubMed ID: 1961728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes.
    Willerson JT; Golino P; Eidt J; Yao SK; Buja LM
    Am J Cardiol; 1990 Nov; 66(16):48G-53G. PubMed ID: 2146868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries.
    Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1988; 101():125-36. PubMed ID: 3269674
    [No Abstract]   [Full Text] [Related]  

  • 60. [Kinetics of cellular response. Signal transduction in the second messenger system].
    Vrzheshch PV
    Vestn Akad Med Nauk SSSR; 1991; (10):57-63. PubMed ID: 1801464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.